NVO - Novo Nordisk to buy Canadian weight loss drug developer Inversago
2023-08-10 12:03:57 ET
More on Novo Nordisk
- Novo Nordisk A/S ( NVO ) Q2 2023 Earnings Call Transcript
- Novo Nordisk: High Valuation Reflects Promising Outlook In Obesity Care
- Novo Nordisk: Denmark's Coca-Cola
- The Case For Novo Nordisk: Growth, Dividends, And A New Treatment Frontier
- Seeking Alpha’s Quant Rating on Novo Nordisk
- Earnings data for Novo Nordisk
For further details see:
Novo Nordisk to buy Canadian weight loss drug developer Inversago